Cite
APA Citation
Brown, L. C., Tucker, M. D., Sedhom, R., Schwartz, E. B., Zhu, J., Kao, C., Labriola, M. K., Gupta, R. T., Marin, D., Wu, Y., Gupta, S., Zhang, T., Harrison, M. R., George, D. J., Alva, A., Antonarakis, E. S., & Armstrong, A. J. (2021). lRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for immunotherapy of cancer, 9(3), . http://access.bl.uk/ark:/81055/vdc_100127583877.0x000019